Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-CHOP21 in elderly untreated DLBCL
2007-003560-21Phase 2Completed
- Sponsor
- Gimurell
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Gimurell. Primary endpoints: Feasibility and toxicity of LR-CHOP21, Dose-limiting toxicity and maximum tolerated dose of lenalidomide and 3 more. Started Oct 2007; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2007-003560-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003560-21.